Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Sammy Chebon"'
Autor:
Phillip Scheinberg, Diego Cle, John Edwards, Valentina Giai, Marek Hus, Jin Seok Kim, Cristina Barrenetxea Lekue, Zsolt Nagy, Erfan Nur, Jens Panse, Yasutaka Ueda, Mustafa Nuri Yenerel, Anita Appius, Nadiesh Balachandran, Sammy Chebon, Brittany Gentile, Simon Buatois, Austin Kulasekararaj
Publikováno v:
HemaSphere, Vol 7, p e45540d8 (2023)
Externí odkaz:
https://doaj.org/article/2d2502a5b31c44548849194a5c1b9631
Autor:
Michael U. Callaghan, Elina Asikanius, Michaela Lehle, Johannes Oldenburg, Johnny Mahlangu, Marianne Uguen, Sammy Chebon, Rebecca Kruse‐Jarres, Víctor Jiménez‐Yuste, Midori Shima, Peter Trask, Christine L. Kempton, Craig M. Kessler, Gallia G. Levy, Flora Peyvandi
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 6, Iss 6, Pp n/a-n/a (2022)
Abstract Background Bleeding in people with hemophilia A can be life threatening, and intra‐articular bleeds can result in joint damage. Most clinical studies focus on treated bleeds, while bleeds not treated with coagulation factor(s) (untreated b
Externí odkaz:
https://doaj.org/article/e0003f2e961e49a1b507a404d3f16f57
Autor:
Amy D. Shapiro, Sylvia von Mackensen, Michael U. Callaghan, Ido Paz-Priel, Midori Shima, Steven W. Pipe, Víctor Jiménez-Yuste, Claude Negrier, Gallia G. Levy, Markus Niggli, Johnny Mahlangu, Sammy Chebon, Avrita Campinha-Bacote, Mark W. Skinner, Michaela Lehle, Johannes Oldenburg
Publikováno v:
Haemophilia
Introduction Severe haemophilia A (HA) has a major impact on health‐related quality of life (HRQoL). Aim Assess the impact of emicizumab on HRQoL in persons with severe HA (PwHA) without factor VIII (FVIII) inhibitors in the phase 3 HAVEN 3 and 4 s
Autor:
Rebecca Kruse-Jarres, Flora Peyvandi, Johannes Oldenburg, Tiffany Chang, Sammy Chebon, Michelle Y. Doral, Stacy E. Croteau, Thierry Lambert, Christine L. Kempton, Steven W. Pipe, Richard H. Ko, Benjamin Trzaskoma, Christophe Dhalluin, Nives Selak Bienz, Markus Niggli, Michaela Lehle, Ido Paz-Priel, Guy Young, Víctor Jiménez-Yuste
Publikováno v:
Blood advances.
Many people with hemophilia A (PwHA) undergo surgery in their lifetime, often because of complications of their disease. Emicizumab is the first bispecific monoclonal antibody prophylactic therapy for PwHA, and its efficacy and safety have been previ
Autor:
Sammy Chebon, Claire Petry, Thomas Emrich, Ido Paz-Priel, Tiffany Chang, Monet Howard, Koichiro Yoneyama, Anna Kiialainen, Markus Niggli, Christophe Schmitt, Elena Fernandez
Publikováno v:
Haemophilia : the official journal of the World Federation of Hemophilia. 27(6)
Introduction Emicizumab is a humanised, bispecific monoclonal antibody mimicking the cofactor function of activated factor (F)VIII. It is indicated for routine prophylaxis of bleeding episodes in persons with haemophilia A (PwHA) with/without FVIII i
Autor:
Michael U. Callaghan, Elina Asikanius, Johnny Mahlangu, Maria Elisa Mancuso, Christophe Schmitt, Michaela Lehle, Sammy Chebon, Víctor Jiménez-Yuste, Peter J. Kuebler, Markus Niggli, Rebecca Kruse-Jarres, Nives Selak Bienz, Ido Paz-Priel, Claude Negrier, Midori Shima, Guy Young, Steven W. Pipe, Tiffany Chang, Johannes Oldenburg, Gallia G. Levy
Publikováno v:
Blood. 136:3-5
Introduction: Emicizumab-a subcutaneously administered, bispecific, humanized, monoclonal antibody-promotes effective hemostasis in people with hemophilia A (PwHA). The primary efficacy and safety of emicizumab were reported previously, but long-term
Autor:
Markus Niggli, Simone Schlagmüller, Elvira Schmidt, Susan C. Edwards, Max Zortel, Roger J. Hampton, Ido Paz-Priel, Sammy Chebon, Anadi Mahajan, J.-P. Flacke, Cedric Revil, Adriana Reyes, Elina Asikanius
Publikováno v:
Current Medical Research and Opinion. 35:2079-2087
Objectives: To compare the efficacy of emicizumab prophylaxis with that of factor VIII (FVIII) prophylaxis in patients with hemophilia A without inhibitors using two approaches: network meta-analyses (NMA) and additional sub-group analyses from the H
Autor:
Peter Trask, Víctor Jiménez-Yuste, Johnny Mahlangu, Michaela Lehle, Sylvia von Mackensen, Ramiro Núñez, Huyen Tran, Johannes Oldenburg, Flora Peyvandi, Sammy Chebon
Publikováno v:
Haemophilia : the official journal of the World Federation of HemophiliaREFERENCES. 27(3)
Introduction Real-world data on health-related outcomes in persons with haemophilia A (PwHA) can provide useful information for improving patient care. The global, non-interventional study (NIS; NCT02476942) prospectively collected high-quality data
Autor:
Elvira Schmidt, Susan C. Edwards, Max Zortel, Sammy Chebon, Adriana Reyes, Markus Niggli, Ido Paz-Priel, Roger J. Hampton, Elina Asikanius, Simone Schlagmüller, Anadi Mahajan, J.-P. Flacke, Cedric Revil
Publikováno v:
Current medical research and opinion. 36(7)
Dear Editor,We thank Jain and Lethagen for the opportunity to clarify some points of interest.As outlined in Mahlangu et al.1, emicizumab prophylaxis has demonstrated a statistically significant an...
Autor:
Michaela Lehle, Elena Santagostino, Maria Elisa Mancuso, Sammy Chebon, Johnny Mahlangu, Rebecca Kruse-Jarres, Nives Selak Bienz, Sylvia von Mackensen, Víctor Jiménez-Yuste, Johannes Oldenburg, Peter Trask, Gallia G. Levy, Elina Asikanius, Midori Shima
Publikováno v:
Biblos-e Archivo. Repositorio Institucional de la UAM
instname
Biblos-e Archivo: Repositorio Institucional de la UAM
Universidad Autónoma de Madrid
instname
Biblos-e Archivo: Repositorio Institucional de la UAM
Universidad Autónoma de Madrid
Background: Data regarding management of pediatric persons with hemophilia A (PwHA) with factor VIII (FVIII) inhibitors are limited. This prospective noninterventional study (NCT02476942) evaluated annualized bleeding rates (ABRs), safety, and health